Overview

A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Pemetrexed